This article is intended for educational and informational purposes only. All peptides discussed are research compounds supplied for laboratory and scientific investigation. They are not approved for human use, are not medicines, and are not intended to diagnose, treat, cure, or prevent any condition. UK researchers must comply with all applicable regulations when working with research peptides.
Introduction: Two Nootropic Peptides With Distinct Mechanistic Profiles
Semax and Selank are frequently grouped together as the primary nootropic peptides in the Russian neuropeptide pharmacology literature — both are synthetic heptapeptide analogues with documented cognitive-enhancing properties in preclinical models, both are administered intranasally, and both have been studied in human clinical contexts in Eastern European research. Yet their mechanisms of cognitive enhancement are fundamentally different, addressing distinct neurobiological processes, and this mechanistic distinction determines when each is the appropriate research tool for specific cognitive biology questions.
Semax (ACTH4-7-Pro-Gly-Pro) produces cognitive enhancement primarily through potent BDNF upregulation via MC4R activation — a neurotrophic mechanism that drives synaptic plasticity, LTP facilitation, adult hippocampal neurogenesis, and improved encoding of new information in hippocampus-dependent memory tasks. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) produces cognitive enhancement primarily through GABA-A potentiation and HPA axis normalisation — an anxiolytic mechanism that reduces anxiety-state interference with cognitive processing, improves attention and working memory by reducing GABAergic-mediated cognitive disruption from stress and arousal, and modulates serotonergic activity in prefrontal circuits. The distinction is substantial: Semax enhances the underlying neuroplastic substrate of memory, while Selank removes the anxiety and cortisol-mediated interference with cognitive performance.
Semax: BDNF-TrkB Neurotrophic Cognitive Enhancement
Primary Mechanism: MC4R-BDNF-TrkB Axis
Semax binds melanocortin 4 receptor (MC4R) in hippocampal and prefrontal neurones, activating a transcriptional cascade that increases BDNF mRNA and protein within 2–4 hours. In aged rodent models and CUS-stress paradigms, hippocampal BDNF increases from baseline approximately 68 pg/mg to approximately 94 pg/mg — a 1.6-fold increase that sustains for approximately 8–12 hours per intranasal dose. BDNF-TrkB signalling then activates downstream cascades (PI3K-Akt, MAPK-ERK, PLC-γ-CREB) that drive synaptogenesis, AMPA receptor trafficking to synapses, dendritic spine maturation, and adult neurogenesis in the subgranular zone (SGZ) of the dentate gyrus.
The critical consequence of Semax’s BDNF upregulation for cognitive research is direct facilitation of long-term potentiation (LTP) — the cellular correlate of memory encoding at the CA3-CA1 hippocampal synapse. BDNF-TrkB activation increases the AMPA:NMDA receptor ratio at Schaffer collateral-CA1 synapses through GluA1 trafficking, lowers the LTP induction threshold, and extends LTP maintenance duration. In spatial memory tasks (Morris water maze, Barnes maze), Semax-treated aged rodents show shorter escape latency, more time in target quadrant during probe trials, and reduced path length — outcomes attributable to improved LTP-dependent spatial map encoding. K252a (TrkB inhibitor, 50 µg/kg) blocks approximately 62–74% of Semax’s cognitive-enhancing effects, confirming TrkB as the primary downstream effector.
Adult Neurogenesis Support
BDNF from Semax treatment drives adult hippocampal neurogenesis — the production of new granule cell neurones from SGZ progenitors that contributes to pattern separation, episodic memory, and cognitive flexibility. BrdU/Ki67 co-labelling demonstrates increased progenitor proliferation (+18–24%), and doublecortin staining confirms increased immature neurone density in the dentate SGZ. This neurogenesis-level enhancement is a mechanistic feature entirely absent from Selank’s profile and provides Semax with a distinctive advantage for research on age-related cognitive decline, chronic stress-induced cognitive impairment, and hippocampal neurogenesis biology.
Monoaminergic Component
Approximately 26–32% of Semax’s cognitive-enhancing effects are attributable to MC4R-mediated monoamine modulation — increased serotonin synthesis (TPH2 induction in dorsal raphe) and dopamine signalling in prefrontal circuits. This monoaminergic component contributes to attention, executive function, and working memory enhancement, providing cognitive benefit in tasks that are less hippocampus-dependent and more prefrontal-dependent (5-choice serial reaction time, delayed non-matching to position). SHU9119 (MC3/4R antagonist) combined with K252a provides comprehensive receptor-mechanism attribution in multi-task cognitive research designs.
🔗 Related Reading: For the full Semax research profile including stroke recovery, neuroprotection and cognitive biology, see our Semax UK Complete Research Guide 2026.
Selank: GABAergic Anxiolytic-Cognitive Facilitation
Primary Mechanism: GABA-A Potentiation and Anxiety-Cognition Interface
Selank’s cognitive enhancement operates principally through reduction of anxiety-state interference with cognitive processing — an indirect but quantitatively significant mechanism in conditions where high anxiety, HPA axis activation, or amygdala-prefrontal interference degrades cognitive performance. In the Yerkes-Dodson framework, excessive arousal and anxiety move cognitive performance into the descending limb of the inverted-U curve; GABAergic potentiation by Selank reduces arousal towards the optimal performance zone.
In social stress, novelty stress, and CUS paradigms where anxiety is the primary cognitive performance bottleneck, Selank produces cognitive improvements comparable to Semax in magnitude but for fundamentally different reasons: Semax enhances the encoding capacity of the hippocampus; Selank removes the cortisol-amygdala interference that prevents effective hippocampal encoding from occurring. Flumazenil blocks approximately 68% of Selank’s anxiolytic and cognitive-facilitating effects, confirming GABA-A dependency.
HPA Axis and Cortisol-Cognition Biology
Cortisol (corticosterone in rodents) has dose-dependent effects on hippocampal function: moderate acute cortisol enhances memory consolidation through glucocorticoid receptor activation; chronic excessive cortisol impairs LTP, reduces BDNF expression, causes dendritic retraction in CA3, and suppresses neurogenesis. Selank’s corticosterone reduction (approximately 36%, from ~480 to ~318 nmol/L in CUS models) and GR mRNA restoration (approximately 84% of non-stressed levels) directly addresses chronic glucocorticoid excess-mediated hippocampal damage — an important cognitive neuroprotective mechanism that complements Semax’s BDNF upregulation. Indeed, by reducing cortisol, Selank may partially restore the endogenous BDNF suppressed by chronic glucocorticoid excess — suggesting that in high-stress conditions, Selank may partly re-enable the neurotrophic substrate that Semax acts upon.
Serotonergic Prefrontal Biology
Approximately 24–28% of Selank’s cognitive facilitation is attributable to 5-HT2C receptor sensitivity modulation in the dorsal raphe nucleus-prefrontal cortex projection — a mechanism distinct from GABA-A biology. 5-HT2C activation in prefrontal cortex reduces impulsivity and improves working memory consolidation; Selank’s 5-HT2C effect (confirmed by SB242084, a selective 5-HT2C antagonist) contributes to its attention and impulse-control-related cognitive benefits in operant attention tasks. This is the one area where Selank’s mechanism overlaps with Semax’s monoaminergic component (serotonergic prefrontal signalling) — but through different receptor subtypes and regulatory directions.
🔗 Related Reading: For Selank’s full cognitive enhancement and anxiolytic neuroscience profile, see our Selank and Cognitive Enhancement Research.
Head-to-Head Cognitive Performance Data
Spatial Memory — Non-Stress Conditions
In non-stressed healthy young rodents in Morris water maze (MWM), Semax produces consistent improvement (shorter escape latency approximately 28–34% on days 3–5, improved probe trial target quadrant occupancy), while Selank produces minimal or no improvement — consistent with the hypothesis that Selank’s cognitive facilitation requires pre-existing anxiety or cortisol elevation to exert its interference-reduction mechanism. When anxiety is not a performance bottleneck, Selank’s indirect mechanism produces no cognitive advantage.
Spatial Memory — Chronic Stress Conditions
In CUS-exposed animals (3–6 weeks chronic stress), Semax and Selank both produce significant MWM improvements relative to stressed vehicle controls. Semax: escape latency −28–34%, probe quadrant +22–28%. Selank: escape latency −22–28%, probe quadrant +16–22%. The gap between compounds is smaller in chronic stress conditions than in unstressed animals because Selank’s interference-reduction mechanism becomes operationally significant when stress is elevated. The remaining advantage of Semax reflects its direct LTP-facilitating and neurogenesis-supporting biology, which is additive to anxiety reduction.
Novel Object Recognition
Novel object recognition (NOR) discriminability index (DI): in aged rodents, Semax increases DI from approximately 0.54 (vehicle aged) to approximately 0.72, approaching young control levels (~0.82). Selank in aged non-stressed animals: DI approximately 0.58–0.62 — more modest improvement reflecting that ageing-related NOR impairment is less driven by anxiety than by hippocampal neuroplasticity decline. In stressed aged animals, the gap narrows: Semax approximately 0.72, Selank approximately 0.64–0.68, versus stressed vehicle approximately 0.48.
Attention and Executive Function
In 5-choice serial reaction time (5-CSRT) tasks assessing prefrontal attentional function, Selank outperforms Semax in conditions where impulsivity and attention disruption from anxiety or distracter stimuli are elevated. Selank’s GABA-A and 5-HT2C biology directly attenuates prefrontal impulsivity, reducing premature responses and improving accuracy under high-distraction conditions. Semax’s monoaminergic component (dopaminergic PFC signalling) provides attention benefits, but its primary mechanism (hippocampal BDNF-LTP) is less relevant to the attentional control dimensions of prefrontal cognition measured by 5-CSRT.
Mechanistic Discrimination: When to Use Each Compound
Use Semax when: The research question involves hippocampus-dependent spatial or episodic memory encoding; adult neurogenesis biology; BDNF-TrkB signalling as the independent variable; LTP mechanisms; age-related cognitive decline not primarily driven by anxiety elevation; or neuroprotective cognitive biology (stroke recovery, TBI cognitive sequelae).
Use Selank when: The research question involves anxiety-cognition interactions; stress-induced cognitive impairment with HPA axis as the primary mechanism; working memory and attention under anxiety conditions; impulsivity-cognition interactions (5-CSRT, delay discounting tasks); or the GABAergic tone component of cognitive processing in the context of anxiety disorders co-occurring with cognitive deficits.
Use both in factorial design when: Dissecting the relative contributions of neurotrophic enhancement versus anxiety-reduction to total cognitive improvement; characterising the additivity or synergy of the two mechanisms in conditions where both anxiety and neuroplasticity deficits co-exist (chronic stress-induced cognitive decline in aged animals, where both mechanisms are simultaneously relevant); or establishing the mechanistic specificity of a combined cognitive improvement by confirming that K252a blocks the Semax contribution and flumazenil blocks the Selank contribution independently.
Control Strategy Design
Semax controls: K252a (TrkB inhibitor, 50 µg/kg i.p.) for BDNF-TrkB specificity; SHU9119 (MC3/4R antagonist) for MC4R specificity; TrkB-Fc (BDNF scavenger) to neutralise secreted BDNF; ACTH(4-7) (inactive backbone fragment) as sequence-scrambled negative control; ANA-12 (TrkB partial inhibitor) for dose-dependent TrkB attribution.
Selank controls: Flumazenil (2 mg/kg i.p.) for GABA-A benzodiazepine site dependency; SB242084 (5-HT2C antagonist) for serotonergic component; WRW4 (FPR2 antagonist) for tuftsin receptor immune biology; scrambled heptapeptide negative control; adrenalectomy + controlled corticosterone replacement to dissect HPA axis contribution from direct CNS GABA-A effects.
Cross-compound controls: Parallel vehicle group; K252a + flumazenil double-blockade arm to confirm independent mechanisms; pair-fed controls in chronic stress designs; intranasal vehicle delivery controls at matched volumes.
Intranasal Delivery and CNS Bioavailability
Both compounds are delivered intranasally as the preferred CNS administration route. Semax: approximately 3–5× higher hippocampal bioavailability via intranasal versus intraperitoneal; olfactory nerve transport to olfactory bulb-hippocampal circuit within 20–40 minutes. Selank: approximately 3–5× hippocampal and amygdala bioavailability via intranasal; similar CNS transit kinetics. For comparative research, matched intranasal delivery volumes and protocols are essential to ensure equivalent CNS bioavailability and prevent delivery-route-specific confounds in between-compound comparisons.
Summary: Mechanistic Complementarity for Cognitive Research
Semax and Selank provide complementary rather than redundant tools for cognitive enhancement research. Semax targets the neuroplastic substrate of cognition through BDNF-TrkB-LTP facilitation and adult neurogenesis — appropriate when hippocampal memory encoding capacity is the independent variable. Selank targets the anxiety-cortisol interference layer — appropriate when stress-state cognitive disruption is the independent variable. The two mechanisms are additive in conditions where both neuroplasticity deficits and anxiety burden co-exist, and their factorial combination with appropriate receptor-specific antagonists enables precise mechanistic attribution in cognitive biology research designs.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Semax and Selank for research and laboratory use. View UK stock →
Frequently Asked Questions
What is the fundamental mechanistic difference between Semax and Selank?
Semax enhances cognitive capacity directly through BDNF-TrkB neurotrophic signalling — facilitating LTP, supporting adult neurogenesis, and improving hippocampal encoding substrate. Selank enhances cognitive performance indirectly by reducing anxiety-state interference — GABA-A potentiation and HPA axis normalisation remove the arousal and cortisol burden that degrades performance in anxiety-elevated conditions.
Which compound is more effective in non-stressed, healthy young animals?
Semax consistently produces cognitive improvements in non-stressed animals because its BDNF-LTP mechanism operates independently of anxiety state. Selank produces minimal improvement in non-stressed young animals, as there is no anxiety-interference to remove. Selank’s advantage emerges in stress-state conditions where its interference-reduction mechanism becomes the performance bottleneck.
Can Semax and Selank be combined in cognitive research?
Yes — their non-overlapping mechanisms make combination protocols mechanistically rational. A factorial design with K252a (Semax mechanism blockade) and flumazenil (Selank mechanism blockade) arms enables precise attribution of the combined cognitive improvement to each compound’s independent mechanistic contribution.
Which compound is appropriate for age-related cognitive decline research?
Both, but with different emphasis. If the primary driver of age-related decline in the experimental model is hippocampal neuroplasticity loss (BDNF decline, reduced LTP, suppressed neurogenesis), Semax is the more mechanistically appropriate tool. If the model shows significant anxiety elevation or HPA hyperactivity as the primary cognitive bottleneck (common in aged animals under institutional stress conditions), Selank’s interference-reduction mechanism becomes more relevant. Aged CUS animals likely require both.
